OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal disease, with very few therapeutic options. Given a paucity of qualitative research to the perspective of patients and other stakeholders in IPF, we sought to identify issues associated with the benefits and risks of emerging treatments and other issues relevant to design of a survey for assessing patient preferences for IPF treatments. METHODS: Semi-structured key informant interviews were conducted, predominately via telephone, with a range of stakeholder perspectives identified through partnership with a national advocacy organization using a combination of purposive and snowball sampling. Stakeholders were asked guiding questions related to emerging trends impacting IPF patients, likely benefits and risks of emerging treatments, and the outcomes most relevant to patients. Detailed and de-identified field notes were analyzed using interpretive phenomenological analysis (IPA), and a taxonomy of key themes was developed. RESULTS: A total of 20 interviews (participation rate 63%) were conducted with patients/advocates/caregivers (n = 7), providers/researchers (n = 8), and experts associated with policy/industry (n = 5). All interviewees expressed great hope with regards to emerging treatments. Three super-ordinate themes emerged: impact of emerging therapies (spanning the benefits, risks, and unintended consequences of emerging therapies); documenting the patient experience (spanning measuring patient-reported outcomes and quality of life and understanding the burden of disease); and coping with disease progression (including symptom mitigation, lung transplantation, and end-of-life considerations). CONCLUSIONS: In identifying issues associated with emerging IPF treatments, we demonstrate the value of qualitative research in understanding the views of diverse stakeholders and in providing a basis for future survey research. As such, qualitative methods should play an important role in understanding the benefits and risks of emerging therapies and in promoting patient-centered drug development.
OBJECTIVE:Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal disease, with very few therapeutic options. Given a paucity of qualitative research to the perspective of patients and other stakeholders in IPF, we sought to identify issues associated with the benefits and risks of emerging treatments and other issues relevant to design of a survey for assessing patient preferences for IPF treatments. METHODS: Semi-structured key informant interviews were conducted, predominately via telephone, with a range of stakeholder perspectives identified through partnership with a national advocacy organization using a combination of purposive and snowball sampling. Stakeholders were asked guiding questions related to emerging trends impacting IPF patients, likely benefits and risks of emerging treatments, and the outcomes most relevant to patients. Detailed and de-identified field notes were analyzed using interpretive phenomenological analysis (IPA), and a taxonomy of key themes was developed. RESULTS: A total of 20 interviews (participation rate 63%) were conducted with patients/advocates/caregivers (n = 7), providers/researchers (n = 8), and experts associated with policy/industry (n = 5). All interviewees expressed great hope with regards to emerging treatments. Three super-ordinate themes emerged: impact of emerging therapies (spanning the benefits, risks, and unintended consequences of emerging therapies); documenting the patient experience (spanning measuring patient-reported outcomes and quality of life and understanding the burden of disease); and coping with disease progression (including symptom mitigation, lung transplantation, and end-of-life considerations). CONCLUSIONS: In identifying issues associated with emerging IPF treatments, we demonstrate the value of qualitative research in understanding the views of diverse stakeholders and in providing a basis for future survey research. As such, qualitative methods should play an important role in understanding the benefits and risks of emerging therapies and in promoting patient-centered drug development.
Authors: Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster Journal: Am J Respir Crit Care Med Date: 2006-06-29 Impact factor: 21.405
Authors: Harold R Collard; Gregory Tino; Paul W Noble; Mark A Shreve; Maureen Michaels; Bruce Carlson; Marvin I Schwarz Journal: Respir Med Date: 2006-11-14 Impact factor: 3.415
Authors: Maureen R Horton; Victoria Santopietro; Leena Mathew; Karen M Horton; Albert J Polito; Mark C Liu; Sonye K Danoff; Noah Lechtzin Journal: Ann Intern Med Date: 2012-09-18 Impact factor: 25.391
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Mirjam J G van Manen; Michael Kreuter; Bernt van den Blink; Ute Oltmanns; Karin Palmowski; Eva Brunnemer; Simone Hummler; Nelleke C Tak; Leon van den Toorn; Jelle Miedema; Henk C Hoogsteden; Marlies S Wijsenbeek Journal: ERJ Open Res Date: 2017-02-14
Authors: Merel L Kimman; Adrienne H Rotteveel; Marlies Wijsenbeek; Rémy Mostard; Nelleke C Tak; Xana van Jaarsveld; Marjolein Storm; Kioa L Wijnsma; Marielle Gelens; Nicole C A J van de Kar; Jack Wetzels; Carmen D Dirksen Journal: Patient Date: 2017-10 Impact factor: 3.883
Authors: Ilene L Hollin; Anne Ef Dimmock; John Fp Bridges; Sonye K Danoff; Rebecca Bascom Journal: Patient Prefer Adherence Date: 2019-05-16 Impact factor: 2.711
Authors: Rosanne Janssens; Eline van Overbeeke; Lotte Verswijvel; Lissa Meeusen; Carolien Coenegrachts; Kim Pauwels; Marc Dooms; Hilde Stevens; Steven Simoens; Isabelle Huys Journal: Front Med (Lausanne) Date: 2018-10-11